Filings Radar

SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.

Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.

Bandwidth Inc. (BAND)

8-K Other material confidence 80% filed 2026-06-18 Item 8.01

Bandwidth Inc. repurchased approximately $122.5 million in aggregate principal amount of its 2028 notes for $116.5 million in cash, reducing outstanding debt by over 80% and materially altering the company's financial structure and leverage profile.

View raw filing on EDGAR →

Arq, Inc. (ARQ)

8-K Exec appointment confidence 92% filed 2026-06-18 Item 5.02

The filing discloses the appointment of Peter Owino as Interim Chief Accounting Officer effective June 12, 2026, and the designation of Bob Rasmus as principal financial officer. While the section also includes compensatory terms (hourly fee of $350 capped at $63,000 monthly), the principal disclosed action is the appointment of individuals to key accounting and financial officer roles. The appointment of an interim CAO to fill a principal accounting officer position is material to investors assessing the company's financial reporting infrastructure.

View raw filing on EDGAR →

Oncology Institute, Inc. (TOIIW)

8-K Shareholder vote confidence 98% filed 2026-06-18 Item 5.07

This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on June 17, 2026, filed under Item 5.07. The filing reports voting outcomes on four proposals: election of eight directors, ratification of BDO USA as independent auditor, Say-on-Pay advisory vote approval, and Say-on-Frequency advisory vote (annual frequency approved). The detailed vote tallies for each proposal and nominee are provided, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and governance.

View raw filing on EDGAR →

ULTRAPAR HOLDINGS INC (UGP)

6-K Dividend Distribution confidence 75% filed 2026-06-18

The Board of Directors approved a share buyback program authorizing the repurchase of up to 18 million common shares (1.61% of capital stock) through June 17, 2027, for use in stock-based incentive plans, treasury maintenance, or subsequent sale/cancellation. While technically a capital allocation decision, share repurchases are classified as dividend_distribution under the taxonomy as they represent a return of capital to shareholders. The program is material as it involves significant authorized spending (up to R$7.66 billion in available reserves) and affects shareholder value and capital structure.

View raw filing on EDGAR →

ULTRAPAR HOLDINGS INC (UGP)

6-K Dividend Distribution confidence 75% filed 2026-06-18

Ultrapar's Board of Directors approved a share buyback program on June 17, 2026, authorizing repurchase of up to 18 million common shares (1.61% of share capital) over 12 months. While share repurchases are capital-allocation events distinct from dividends, they function as a return of capital to shareholders and are classified under the dividend_distribution category as a form of shareholder distribution. The program is material as it represents a significant capital deployment decision affecting shareholder value and the company's financial position.

View raw filing on EDGAR →

TRINITY BIOTECH PLC (TRIB)

6-K Earnings release confidence 92% filed 2026-06-18 EX-99.1

This exhibit is a press release announcing Q1 2026 financial results for Trinity Biotech, including revenue of $10.8m (43% increase YoY), gross margin improvement from 25.2% to 35.4%, and net loss reduction from $8.8m to $4.4m. The disclosure also announces significant product orders (2+ million TrinScreen HIV tests) expected to contribute to 2026 revenue and profitability targets. This is a material earnings release with forward-looking guidance affecting investor assessment of financial performance and outlook.

View raw filing on EDGAR →

Liberty Media Corp (FWONB)

8-K Other material confidence 72% filed 2026-06-18 Item 7.01

Liberty Media announced the closing of a debt repricing for its MotoGP subsidiary, reducing total debt by approximately $114 million equivalent and lowering interest margins on Term Loan B (from 2.50% to 2.25%) and adjusting leverage-based pricing bands. While this is a material refinancing event affecting a significant subsidiary's capital structure and debt service costs, it does not fit cleanly into the standard 8-K taxonomy—it is neither a covenant breach, a material impairment, nor a traditional M&A activity, but rather a proactive debt restructuring disclosed under Regulation FD.

View raw filing on EDGAR →

NEWS CORP (NWSLL)

8-K Dividend Distribution confidence 85% filed 2026-06-18 Item 8.01

News Corporation discloses daily share repurchase activity under its $1 billion Repurchase Program authorized July 15, 2025. The Item 8.01 filing reports specific buyback transactions (8.1M+ Class A shares and 76.7K Class B shares purchased on 18 June 2026 for ~$205.8M aggregate consideration) and cumulative progress (~$317.1M of $1B authorized). Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution taxonomy as a return-of-capital mechanism, distinct from operational or governance events.

View raw filing on EDGAR →

New Mountain Finance Corp (NMFCZ)

8-K Dilutive issuance confidence 75% filed 2026-06-18 Item 8.01

New Mountain Finance Corp entered into a Seventh Supplement to its Note Purchase Agreement authorizing the issuance of $150 million in aggregate principal amount of senior notes ($40M Tranche A, $35M Tranche B, $75M Tranche C) in a private placement relying on Section 4(a)(2) of the Securities Act. The issuance will be used for general corporate purposes, investments, and debt repayment, materially increasing the Company's leverage.

View raw filing on EDGAR →

RECURSION PHARMACEUTICALS, INC. (RXRX)

8-K Shareholder vote confidence 98% filed 2026-06-18 Item 5.07

This is a classic Item 5.07 disclosure reporting the results of Recursion Pharmaceuticals' 2026 annual meeting of stockholders held on June 17, 2026. The filing presents voting results for three proposals: election of Class II directors (Najat Khan and Franziska Michor), advisory approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. These are routine but material shareholder votes that affect corporate governance and audit oversight.

View raw filing on EDGAR →

ADVANCED DRAINAGE SYSTEMS, INC. (WMS)

8-K Other material confidence 65% filed 2026-06-18 Item 7.01

Advanced Drainage Systems disclosed a 2026 Investor Day event with presentation of fiscal 2030 outlook and growth projections. While Item 7.01 (Regulation FD Disclosure) is typically used for non-material investor communications, the disclosure of forward-looking guidance for fiscal 2030 targets (10% CAGR sales growth, 28-29% margin expansion, 45-50% free cash flow conversion) and unveiling of a multi-year strategic outlook constitutes material forward-looking information that would affect investor assessment. However, this does not fit neatly into the specific event taxonomy (not earnings release, not M&A, not an executive change, etc.), warranting classification as other_material.

View raw filing on EDGAR →

NextDecade Corp (NEXT)

8-K M&A activity confidence 75% filed 2026-06-18 Item 1.01

NextDecade's indirect subsidiary RGLNG HoldCo Borrower entered into a $1.0 billion term loan credit agreement on June 17, 2026, with proceeds used to make an equity contribution to reduce outstanding borrowings under RGLNG's credit facilities. The transaction involves material restructuring of the Rio Grande LNG project's capital structure with comprehensive collateral arrangements including pledge, security, and intercreditor agreements.

View raw filing on EDGAR →

Caribou Biosciences, Inc. (CRBU)

8-K Shareholder vote confidence 95% filed 2026-06-18 Item 5.07

This is a clear disclosure of shareholder vote results from Caribou Biosciences' June 17, 2026 annual meeting of stockholders, filed under Item 5.07. The filing presents voting tallies for four proposals: election of three Class II directors (all passed), ratification of Deloitte & Touche LLP as auditor (passed), approval of officer exculpation amendment (failed), and approval of meeting adjournment (passed). The election of directors and auditor ratification are material governance events affecting investor assessment of board composition and audit oversight.

View raw filing on EDGAR →

GRAVITY Co., Ltd. (GRVY)

6-K Dividend Distribution confidence 85% filed 2026-06-18

The filing announces closure of the shareholder register from July 1–10, 2026 to determine shareholders eligible for an interim dividend for fiscal year 2026, with a record date of June 30, 2026. Although the specific dividend amount is not yet determined (to be set by the board), the announcement of an interim dividend distribution and the establishment of a record date constitute a material dividend declaration under the dividend_distribution category.

View raw filing on EDGAR →

Commercial Vehicle Group, Inc. (CVGI)

8-K Dilutive issuance confidence 92% filed 2026-06-18 Item 1.01

Commercial Vehicle Group entered into a Capital on Demand™ Sales Agreement with JonesTrading to offer and sell up to $25 million of common stock "at the market" under Rule 415(a)(4). This is a registered direct offering of equity securities that creates potential dilution to existing shareholders. The $25 million offering size and the at-the-market structure are material to investors assessing capital structure and ownership dilution.

View raw filing on EDGAR →

Alight, Inc. / Delaware (ALIT)

8-K Other material confidence 75% filed 2026-06-18 Item 8.01

Alight announced a 1-for-20 reverse stock split effective June 30, 2026, approved by stockholders at the June 10, 2026 Annual Meeting. While reverse stock splits are structural actions that do not change economic ownership, this disclosure is material because it affects the total mix of information available to investors—particularly regarding the company's compliance with NYSE listing standards (the press release explicitly states the split "affirms the Company's commitment to remain on the NYSE by meeting the NYSE's price criteria for continued listing"). The event does not fit neatly into the specific taxonomy categories (not a delisting risk per se, but rather a proactive measure to avoid one), making "other_material" the most appropriate classification.

View raw filing on EDGAR →

CHAIN BRIDGE BANCORP INC (CBNA)

8-K Shareholder vote confidence 98% filed 2026-06-18 Item 5.07

This is a clear disclosure of shareholder voting results from Chain Bridge Bancorp's June 17, 2026 Annual Meeting of Stockholders. The filing reports final vote tallies for two proposals: (1) election of thirteen directors, with detailed vote counts (For/Against/Abstain/Broker Non-Votes) for each nominee, and (2) ratification of Yount, Hyde & Barbour, P.C. as independent auditor. This is a textbook Item 5.07 shareholder vote results disclosure, and the election of directors and auditor ratification are material governance matters affecting investor assessment of board composition and audit oversight.

View raw filing on EDGAR →

Local Bounti Corporation/DE (LOCLW)

8-K Exec departure confidence 75% filed 2026-06-18 Item 5.02

Craig Hurlbert resigned as Executive Chairman and Board member effective June 18, 2026, and Matthew Nordby resigned as Board member and Lead Independent Director effective the same date. While the filing also discloses new Board appointments and committee assignments, the principal disclosed action centers on the departure of two senior directors, particularly Hurlbert who held the Executive Chairman role. The departures are material as they represent significant changes in Board leadership and governance structure.

View raw filing on EDGAR →

Sionna Therapeutics, Inc. (SION)

8-K Shareholder vote confidence 98% filed 2026-06-18 Item 5.07

This is a clear disclosure of shareholder voting results from Sionna Therapeutics' Annual Meeting of Stockholders held on June 17, 2026. The filing reports the voting outcomes for two proposals: (1) election of four Class II directors (H. Edward Fleming, Jr., Marcella Kuhlman Ruddy, Peter A. Thompson, and Joanne Louise Viney), and (2) ratification of Deloitte & Touche LLP as independent auditor. All nominees were elected and the auditor appointment was ratified. This is a routine but material disclosure required under Item 5.07 of Form 8-K.

View raw filing on EDGAR →

Voyager Technologies, Inc./TX (VOYG)

8-K Other material confidence 75% filed 2026-06-18 Item 3.03

Voyager Technologies completed a redomestication from Delaware to Texas on June 18, 2026, converting from a Delaware corporation to a Texas corporation. This structural change materially modifies the governance framework and stockholder rights by shifting from Delaware General Corporation Law to Texas Business Organizations Code, affecting the legal rights and protections of shareholders.

View raw filing on EDGAR →

GOLAR LNG LTD (GLNG)

6-K Earnings release confidence 95% filed 2026-06-18

This 6-K furnishes the unaudited interim financial statements and management's discussion and analysis for the three months ended March 31, 2026. The exhibit includes consolidated statements of operations, comprehensive income, balance sheets, and cash flows, along with detailed MD&A discussing material changes in financial performance. This is a standard quarterly earnings disclosure material to investors assessing the registrant's financial condition and operational performance.

View raw filing on EDGAR →

Vertiv Holdings Co (VRT)

8-K Shareholder vote confidence 98% filed 2026-06-18 Item 5.07

This is a classic Item 5.07 disclosure reporting the results of Vertiv's 2026 Annual Meeting of Stockholders held on June 17, 2026. The filing presents final voting tallies for three proposals: election of eleven directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The detailed vote counts (For, Against, Abstentions, Broker Non-Votes) for each proposal are the core content of the disclosure.

View raw filing on EDGAR →

ARES STRATEGIC INCOME FUND

8-K Other material confidence 65% filed 2026-06-18 Item 2.03

The filing discloses an increase in total commitments under a senior secured revolving credit facility from $4.100 billion to $4.138 billion ($38 million increase). While this represents a modification to an existing direct financial obligation under Item 2.03, it is a routine increase in an existing credit facility with no indication of covenant breach, distress, or material adverse change. The modest 0.93% increase and unchanged other terms suggest this is an administrative expansion rather than a material event triggering financial stress or restructuring concerns typical of the more specific event categories.

View raw filing on EDGAR →

Construction Partners, Inc. (ROAD)

8-K M&A activity confidence 73% filed 2026-06-18 Item 1.01

Construction Partners, Inc. entered into Amendment No. 1 to its Term Loan B Credit Agreement on June 18, 2026, refinancing existing term loans and providing $300 million in incremental term loans, increasing total term loan debt from $839.4 million to $1,139.4 million. This material modification to the Company's capital structure affects leverage ratios, covenants, and debt capacity, materially altering the Company's financial position and flexibility.

View raw filing on EDGAR →

CENTRUS ENERGY CORP (LEU)

8-K M&A activity confidence 85% filed 2026-06-18 Item 8.01

Centrus signed a non-binding letter of intent with Oklo for a significant long-term HALEU supply agreement with deliveries beginning in 2029, covering up to five Aurora powerhouses over multiple years. While non-binding, this represents a material commercial arrangement that contemplates a definitive agreement and could include prepayments, establishing a major customer relationship and revenue stream for Centrus' Piketon facility expansion. The agreement is material to investors assessing Centrus' business prospects and revenue visibility.

View raw filing on EDGAR →

ROKU, INC (ROKU)

8-K Other material confidence 75% filed 2026-06-18 Item 8.01

Roku is filing an 8-K to reflect a material change in segment reporting structure, effective Q1 2026. The company reorganized from two segments (combined Platform) to three reportable segments (Advertising, Subscriptions, and Devices), requiring retrospective restatement of prior period financial information. While the filing explicitly states "This Form 8-K...is not an amendment to the 2025 Form 10-K or a restatement of the financial statements included therein," the retrospective application of segment changes to MD&A, Business, and Financial Statements sections is material to investors' understanding of the company's financial performance and structure. This does not fit cleanly into restatement (which typically involves accounting errors) but represents a significant organizational and reporting change that would affect investor analysis.

View raw filing on EDGAR →

Mondelez International, Inc. (MDLZ)

8-K Exec appointment confidence 95% filed 2026-06-18 Item 5.02

Mondelez International appointed Amit Banati as Executive Vice President and Chief Financial Officer, effective July 1, 2026, reporting directly to the CEO. The appointment includes a base salary of $1,050,000, target incentive of 125%, an equity grant of $5,000,000, and a make-whole award up to $7,000,000. The filing also notes that Luca Zaramella will transition from CFO to Chief Operating Officer.

View raw filing on EDGAR →

CENTRUS ENERGY CORP (LEU)

8-K Other material confidence 73% filed 2026-06-18 Item 1.01

Centrus Energy entered into a Seventh Amendment to its Section 382 Rights Agreement on June 18, 2026, extending the Final Expiration Date from June 30, 2026 to June 30, 2029 and increasing the purchase price for preferred stock. This tax-protection mechanism was approved by stockholders and is material to investors as it preserves the company's ability to utilize substantial NOL carryforwards under Section 382 of the Internal Revenue Code.

View raw filing on EDGAR →

CENTRUS ENERGY CORP (LEU)

8-K Shareholder vote confidence 95% filed 2026-06-18 Item 5.07

Centrus Energy held its 2026 annual meeting of stockholders on June 18, 2026, with voting results disclosed for five proposals: election of six directors, say-on-pay advisory vote, amendment to certificate of incorporation regarding officer exculpation, approval of the Section 382 Rights Agreement extension, and ratification of Deloitte & Touche LLP as independent auditors.

View raw filing on EDGAR →

Honest Company, Inc. (HNST)

8-K Other material confidence 72% filed 2026-06-18 Item 1.01

Honest Company entered into a material definitive lease agreement for approximately 38,240 square feet of corporate headquarters space in Playa Vista, California, with a 10-year initial term and total base rent obligation of approximately $33.4 million (net of rent abatement). This represents a significant capital commitment and strategic operational decision.

View raw filing on EDGAR →

Brilliant Earth Group, Inc. (BRLT)

8-K Shareholder vote confidence 98% filed 2026-06-18 Item 5.07

This is a classic Item 5.07 disclosure reporting the results of the Annual Meeting of Stockholders held on June 17, 2026. The filing presents final voting tallies for two proposals: election of three Class II directors (Eric Grossberg, Attica A. Jaques, and Gavin M. Turner) and ratification of BDO USA, PC as independent auditor. Both proposals passed. Director elections are material governance events affecting the composition of the board.

View raw filing on EDGAR →

DocGo Inc. (DCGO)

8-K Shareholder vote confidence 98% filed 2026-06-18 Item 5.07

This is a classic Item 5.07 disclosure reporting the results of DocGo's 2026 Annual Meeting of Stockholders held on June 16, 2026. The filing presents voting outcomes on six matters: election of two Class II directors (Vina Leite and James M. Travers), advisory approval of named executive officer compensation, approval of a reverse stock split (1-for-5 to 1-for-10), rejection of a corporate opportunity waiver amendment, rejection of an officer exculpation amendment, and ratification of Urish Popeck & Co., LLC as independent auditor. The reverse stock split approval and director elections are material corporate governance events affecting shareholder interests.

View raw filing on EDGAR →

Comstock Holding Companies, Inc. (CHCI)

8-K Shareholder vote confidence 95% filed 2026-06-18 Item 5.07

Stockholders voted at the June 17, 2026 Annual Meeting of Stockholders on three proposals: election of directors (David M. Guernsey and James A. MacCutcheon), ratification of Grant Thornton LLP as independent auditor, and advisory approval of named executive officer compensation. Detailed voting tallies for each proposal are disclosed.

View raw filing on EDGAR →

Comstock Holding Companies, Inc. (CHCI)

8-K Exec appointment confidence 95% filed 2026-06-18 Item 5.02

David Z. Hirsh was appointed as a Class II independent director and Audit Committee member, effective immediately following the June 17, 2026 Annual Meeting. Hirsh brings 30+ years of real estate experience and prior leadership roles at Blackstone and Citigroup.

View raw filing on EDGAR →

HF Foods Group Inc. (HFFG)

8-K Exec appointment confidence 95% filed 2026-06-18 Item 5.02

HF Foods Group Inc. appointed Taylor S. Brown as an independent director of the Board of Directors, effective June 19, 2026, following the Board's decision to increase its size from four to five directors. Mr. Brown brings qualifications in legal, acquisitions, and operational matters.

View raw filing on EDGAR →

Kraft Heinz Co (KHC)

8-K Exec departure confidence 95% filed 2026-06-18 Item 5.02

Cory Onell, Executive Vice President and Chief Omnichannel Sales and Asia Emerging Markets Officer, is stepping down from his role effective June 30, 2026. While the disclosure mentions severance payments and a prorated bonus, the principal disclosed action is the departure of a named executive officer from a significant leadership position. This is material as it affects the company's senior management structure and operational leadership.

View raw filing on EDGAR →

ServiceTitan, Inc. (TTAN)

8-K Shareholder vote confidence 98% filed 2026-06-18 Item 5.07

This is a clear disclosure of shareholder voting results from ServiceTitan's June 17, 2026 Annual Meeting of Stockholders under Item 5.07. The filing reports final voting tallies for three proposals: election of three Class II directors (Michael Brown, Byron Deeter, and Vahe Kuzoyan), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of annual say-on-pay votes. All three proposals passed with substantial majorities, making this a routine but material governance disclosure.

View raw filing on EDGAR →

NovoCure Ltd (NVCR)

8-K Other material confidence 75% filed 2026-06-18 Item 7.01

NovoCure announced topline results from its Phase 3 TRIDENT trial, a pivotal clinical study evaluating TTFields therapy timing in glioblastoma treatment. The trial did not meet its primary endpoint of demonstrating statistically significant overall survival improvement for early initiation (HR 0.953; p=0.519), which is material to investors assessing the company's pipeline and commercial prospects. While this is clinical trial data rather than a traditional earnings release, the negative primary endpoint outcome for a Phase 3 pivotal trial is a material event affecting investor assessment of the registrant's development programs and future revenue potential.

View raw filing on EDGAR →

Editas Medicine, Inc. (EDIT)

8-K Shareholder vote confidence 98% filed 2026-06-18 Item 5.07

This Item 5.07 filing discloses the results of Editas Medicine's 2026 Annual Meeting of Stockholders held on June 17, 2026, including voting outcomes on three matters: election of Class I directors (Bernadette Connaughton and Elliott Levy, M.D.), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents vote tallies (For, Against, Withheld, Abstaining, and Broker Non-Votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder meeting results.

View raw filing on EDGAR →

SOLITARIO RESOURCES CORP. (XPL)

8-K Shareholder vote confidence 95% filed 2026-06-18 Item 5.07

Solitario Resources held its Annual Meeting of Shareholders on June 17, 2026, with voting results disclosed on three matters: election of six directors, advisory vote on executive compensation, and ratification of auditors. The filing reports detailed vote tallies for each proposal.

View raw filing on EDGAR →

Federal Home Loan Bank of New York

8-K Other material confidence 65% filed 2026-06-18 Item 2.03

This Item 2.03 disclosure reports the issuance of consolidated obligations (debt securities) totaling approximately $5.85 billion across multiple tranches with trade dates of 6/15–6/16/2026. While Item 2.03 is nominally for "creation of a direct financial obligation," the filing itself notes that "consolidated obligations issuance is material to the Bank" and explicitly states no judgment has been made as to materiality of particular obligations. The disclosure is routine debt issuance reporting by a Federal Home Loan Bank, not a triggering covenant breach, going-concern issue, or other acute financial stress signal. The event is material to investors (substantial debt issuance affects capital structure and leverage), but does not fit neatly into more specific categories like covenant_breach or material_impairment; it is best classified as other_material.

View raw filing on EDGAR →

Hancock Park Corporate Income, Inc.

8-K Other material confidence 65% filed 2026-06-18 Item 2.02

The filing discloses a Board determination of net asset value (NAV) per share of $6.27 as of June 18, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). While NAV disclosure is material to investors in closed-end funds and similar investment vehicles, this does not constitute a traditional earnings release (which typically includes comprehensive financial results, revenue, net income, and forward guidance). The disclosure is a single valuation metric without accompanying financial statements or earnings data, making it distinct from the earnings_release category but clearly material to shareholders assessing the Company's value.

View raw filing on EDGAR →

Coinbase Global, Inc. (COIN)

8-K Shareholder vote confidence 98% filed 2026-06-18 Item 5.07

This is a clear disclosure of shareholder voting results from Coinbase's June 16, 2026 annual meeting, reporting the election of nine directors and ratification of Deloitte & Touche LLP as independent auditor. The filing presents detailed vote tallies for each nominee and proposal, which is the quintessential content of Item 5.07 shareholder vote results disclosures.

View raw filing on EDGAR →

Valion Bio, Inc. (VBIO)

8-K Dilutive issuance confidence 75% filed 2026-06-18 Item 3.02

The filing discloses Item 3.02 (Unregistered Sales of Equity Securities) with a cross-reference to Item 8.01 for substantive details. Item 3.02 is the dedicated disclosure item for dilutive equity issuances such as private placements and PIPEs. While the actual transaction details are incorporated by reference to Item 8.01 (not shown in this excerpt), the presence of Item 3.02 itself signals an unregistered equity sale, which is material to investors as it affects share dilution and capital structure.

View raw filing on EDGAR →

FOCUS UNIVERSAL INC. (FCUV)

8-K Other material confidence 75% filed 2026-06-18 Item 3.03

The Board approved a 4-to-1 reverse stock split effective June 23, 2026, undertaken to satisfy Nasdaq's $1.00 minimum bid price requirement for continued listing. The reverse split modifies shareholder rights by reducing share count and changing the trading symbol and CUSIP.

View raw filing on EDGAR →

IIOT-OXYS, Inc. (ITOX)

8-K Dilutive issuance confidence 92% filed 2026-06-18 Item 1.01

IIOT-OXYS entered into Amendment No. 1 to a Securities Purchase Agreement on June 12, 2026, authorizing issuance of up to 167 shares of Series D Convertible Preferred Stock, with a Third Additional Closing on June 16, 2026 issuing 30 shares (27 purchased + 3 as equity incentive) to accredited investor GHS under Section 4(a)(2) and Regulation D Rule 506(b). This unregistered private placement of preferred stock materially dilutes existing shareholders and affects the registrant's capital structure.

View raw filing on EDGAR →

Transglobal Management Group, Inc. (TMGI)

8-K M&A activity confidence 92% filed 2026-06-18 Item 5.01

The disclosure describes a transfer of 61 shares of Series A Preferred Stock from Kelly Kirchhoff to Jeff Foster on June 15, 2026, which resulted in a shift of voting control of the Company from Kirchhoff to Foster. The filing explicitly states that "voting control of the Company shifted from Mr. Kirchhoff to Mr. Foster" and that Series A Preferred Stock ownership "provides the holders with voting rights sufficient to control matters submitted to shareholders." This constitutes a material change of control event under Item 5.01, even though no officers or directors formally changed positions.

View raw filing on EDGAR →

Tianci International, Inc. (CIIT)

8-K Dilutive issuance confidence 94% filed 2026-06-18 Item 1.01

Tianci International consummated a registered public offering of 6,055,000 units (4,055,000 standard units and 2,000,000 pre-funded units) at $0.81 per unit on June 17, 2026, generating approximately $4.9 million in gross proceeds. Each unit includes common stock (or pre-funded warrant) and common warrants with anti-dilution provisions, materially diluting existing shareholders.

View raw filing on EDGAR →

Sonoma Pharmaceuticals, Inc. (SNOA)

8-K Dilutive issuance confidence 92% filed 2026-06-18 Item 8.01

The filing discloses an At Market Issuance Sales Agreement (ATM) under which Sonoma Pharmaceuticals may offer and sell shares of common stock through an agent. The company has already sold 173,073 shares for $574,633 and increased the aggregate offering price to $3,641,703 as of the filing date. ATM offerings are classic dilutive equity issuances that signal capital-raising activity and potential shareholder dilution, material to investors assessing ownership stakes and capital structure.

View raw filing on EDGAR →

Lifeway Foods, Inc. (LWAY)

8-K Shareholder vote confidence 98% filed 2026-06-18 Item 5.07

Lifeway Foods held its 2026 Annual Meeting of Shareholders on June 17, 2026, with voting results on four proposals: election of seven directors (Kirk Chartier, Juan Carlos Dalto, Rachel Drori, Andee Harris, Susie Hultquist, Dorri McWhorter, and Julie Smolyansky), ratification of Grant Thornton LLP as independent auditors, advisory approval of executive compensation, and election of Jason Scher. Detailed vote tallies for each proposal are disclosed.

View raw filing on EDGAR →